Table 5.
Reliability statistics for the MAR-scale across disease conditions and modes and frequencies of administration
| Conditionb | Reliability statistics based on Cronbach’s alpha/Guttman Split-half coefficienta (sample size) | |||||
|---|---|---|---|---|---|---|
| Daily orals | Daily injections | Daily topicals | Weekly orals | Weekly injections | Weekly topicals | |
| Diabetes | 0.911/0.807 (2746) | 0.954/0.918 (1078) | 0.993/0.984 (120) | |||
| Arthritis | 0.915/0.826 (2480) | 0.944/0.925 (163) | 0.962/0.917 (244) | 0.979/0.965 (126) | ||
| Lupus | 0.966/0.930 (119) | |||||
| Migraine | 0.914/0.849 (1055) | 0.950/0.875 (413) | ||||
| Osteoporosis | 0.937/0.895 (307) | 0.924/0.824 (330) | ||||
| Pain | 0.887/0.766 (4056) | 0.933/0.851 (172) | 0.934/0.880 (603) | |||
| IBD | 0.931/0.855 (254) | |||||
| GERD/Heartburn | 0.912/0.828 (4442) | 0.959/0.917 (406) | ||||
| Chronic constipation | 0.941/0.900 (393) | |||||
| IBS | 0.884/0.782 (659) | 0.940/0.900 (117) | ||||
| Psoriasis | 0.973/0.949 (137) | 0.899/0.791 (328) | ||||
| Eczema | 0.966/0.898 (171) | 0.842/0.770 (979) | 0.957/0.917 (201) | |||
| Epilepsy | 0.920/0.792 (294) | |||||
| Sleep condition | 0.903/0.834 (2812) | 0.943/0.901 (379) | ||||
| Depression | 0.893/0.775 (4798) | 0.957/0.897 (113) | ||||
| Overactive bladder | 0.912/0.830 (953) | |||||
Notes: aFor medicines, Cronbach’s alpha/Guttman split-half coefficient was calculated only if the sample size was greater than 100. bEczema = Eczema/Atopic Dermatitis/Dermatitis; Sleep condition = Sleep difficulties/Insomnia/Narcolepsy/Sleep Apnea; Pain = Pain/Fibromyalgia/Diabetic Neuropathic Pain; Overactive bladder = Wet/Dry/Stress Urinary Incontinence; Osteoporosis = Osteoporosis/Osteopenia; Arthritis = Rheumatoid Arthritis/Psoriatic Arthritis/Osteoarthritis/Ankylosing Spondylitis; Diabetes = Type 1/Type 2/Latent Autoimmune Diabetes in Adults.
Abbreviations: GERD, GastroEsophageal Reflux Disease; IBD, Inflammatory Bowel Disease; IBS, irritable bowel syndrome.